RPL17 and cancer: Mice were subcutaneously implanted with MC38, B16F10 or MT4 cancer cells and treated with combined PLX4786 and anti-CTLA-4 or anti-PD-1 to determine the effects on tumor growth and on subpopulations of immune cells within the tumor microenvironment.